Clinical Trials Logo
  1. Home
  2. NSCLC
  3. NCT05144997
  4. Details
NCT05144997 Clinical Trial

Lorlatinib Continuation Study

NSCLC Clinical Trial

Official title:
LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05144997
Other study ID # B7461039
Secondary ID 2021-005569-42
Status Recruiting
Phase Phase 4
First received
Last updated
Start date December 28, 2021
Est. completion date December 28, 2026

Study information
Verified date May 2024
Source Pfizer
Contact Pfizer CT.gov Call Center
Phone 1-800-718-1021
Email ClinicalTrials.gov_Inquiries@pfizer.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date December 28, 2026
Est. primary completion date December 28, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1 - Any participant who is receiving study treatment and deriving clinical benefit (as determined by the Principal Investigator) in a Pfizer-sponsored Lorlatinib Parent Study. 2- Participants must agree to follow the reproductive criteria. 3- Adequate Bone Marrow, Liver, Renal, Pancreatic Function Exclusion Criteria: 1 - Female participants who are pregnant or breastfeeding. 2- Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Lorlatinib
ALK-positive NSCL treatment

Locations
Country Name City State
China Beijing Cancer Hospital Beijing Beijing
China Beijing Chest Hospital, Capital Medical University Beijing Beijing
China Beijing Chest Hospital, Capital Medical University Beijing
China University Cancer Hospital Beijing
China Jilin Cancer Hospital Changchun Jilin
China Jilin Cancer Hospital Changchun Jilin
China The first hospital of jilin university Changchun City Jilin
China Hunan Cancer Hospital Changsha Hunan
China Sichuan Cancer Hospital Chengdu Sichuan
China Sichuan Cancer Hospital Chengdu Sichuan
China Fujian Cancer Hospital Fuzhou Fujian
China Guangdong Provincial People's Hospital Guangzhou Guangdong
China Sir Run Shaw Hospital Hangzhou Qiantang District
China The First affiliated Hospital of Anhui Medical University Hefei Anhui
China General Hospital of Eastern Theater Command Nanjing Jiangsu
China Fudan University Shanghai Cancer Center Shanghai
China Shanghai Chest Hospital Shanghai Shanghai
China The Second Affiliated Hospital of PLA Air Force Medical University Xi'an City Shaanxi
France CHU de Rennes - Hôpital Pontchaillou Rennes
France Institut Gustave Roussy Villejuif Cedex
Japan Aichi Cancer Center Hospital Nagoya Aichi
Singapore National Cancer Centre Singapore Singapore
Singapore National Cancer Centre Singapore Singapore
Singapore National University Hospital Singapore
Spain Hospital Universitari Vall d'Hebron Barcelona
Spain Hospital Vall D´Hebron Barcelona Cataluña
Taiwan National Taiwan University Hospital Taipei
United States UC Irvine Health Orange California

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  China,  France,  Japan,  Singapore,  Spain,  Taiwan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events leading to permanent discontinuation of study intervention Safety collection in this study will permit further characterization of the safety profile of lorlatinib Baseline up to approximately 5 years
Primary Number of serious adverse events reported for all participants Safety collection in this study will permit further characterization of the safety profile of lorlatinib Baseline up to approximately 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2

External Links